logo
  

Sandoz: ROSALIA Study With Proposed Biosimilar Denosumab Meets Primary Endpoints

Sandoz reported positive results from the integrated ROSALIA phase I/III clinical trial study for its proposed biosimilar denosumab. The company said the results from the study confirmed the biosimilar matches the reference medicine in terms of pharmacokinetics, pharmacodynamics, efficacy, safety and immunogenicity in the respective indications; and contributes to demonstration of similarity.

In July 2022, the application for the multiple sclerosis proposed biosimilar natalizumab was accepted for review by the FDA and European Medicines Agency. In June 2022, EMA and FDA accepted for review Sandoz applications for the high-concentration formulation 100 mg/mL of its biosimilar adalimumab.

For More Such Health News, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Stocks staged a significant recovery attempt after pulling back sharply in early trading on Wednesday but still ended the day modestly lower. The major averages gave back ground after moving sharply higher over the two previous sessions. Three scientists have shared the Nobel Prize for Chemistry for their work that led to the development of linking molecules together, known as click chemistry, and bioorthogonal chemistry. Morten Meldal and K. Barry Sharpless have laid the foundation for a functional form of chemistry - click chemistry - in which molecular building blocks snap together quickly and efficiently. Carolyn R. Bertozzi The Institute for Supply Management released a report on Wednesday showing a modest slowdown in the pace of growth in U.S. service sector activity in the month of September. The ISM said its services PMI edged down to 56.7 in September from 56.9 in August, although a reading above 50 still indicates growth in the sector.
Follow RTT